Skip to Content

Generic Zoladex Availability

Zoladex is a brand name of goserelin, approved by the FDA in the following formulation(s):

ZOLADEX (goserelin acetate - implant;implantation)

  • Manufacturer: ASTRAZENECA
    Approval date: December 29, 1989
    Strength(s): EQ 3.6MG BASE [RLD]
  • Manufacturer: ASTRAZENECA
    Approval date: January 11, 1996
    Strength(s): EQ 10.8MG BASE [RLD]

Has a generic version of Zoladex been approved?

No. There is currently no therapeutically equivalent version of Zoladex available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zoladex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Automatically operable safety shield system for syringes
    Patent 7,118,552
    Issued: October 10, 2006
    Inventor(s): Shaw; Derek J. & Law; Brian R.
    Assignee(s): AstraZeneca AB
    An automatically operable safety shield system for use with a syringe, the safety shield system including an holder having proximal and distal portions and defining an enclosure into which the syringe may be inserted, an outer shield having proximal and distal portions, mounted outwards from the inner holder being axially movable relative to the inner holder between retracted and extended positions, a spring positioned between a first detent on the inner holder and a second detent on the outer shield, and urging the outer shield to its extended position, the inner holder having at least one first opening and the outer shield having at least one first stop member, the first stop member being engageable with the first opening when the outer shield is in the retracted position, the inner holder having distal to the first opening at least one first indentation, the first stop member being engageable with the first indentation when the outer shield is in the extended position.
    Patent expiration dates:
    • April 13, 2022
      ✓ 
      Drug product
  • Automatically operable safety shield system for syringes
    Patent 7,220,247
    Issued: May 22, 2007
    Inventor(s): Shaw; Derek J & Law; Brian R
    Assignee(s): AstraZeneca AB
    An automatically operable safety shield system for use with a syringe that comprises an inner holder in which said syringe may be inserted and an outer shield mounted outwards from the inner holder axially movable between retracted and extended positions in which a spring positioned between said inner holder and said outer shield urging the outer shield to its extended position and the inner holder having at least one first opening, distally thereto, at least one first indentation, and the outer shield having at least one first stop member engageable with the opening when the outer shield is in the retracted position engageable with the first indentation when the outer shield is in the extended position and the outer shield may be released from its retracted position by action of a trigger positioned within the inner holder or by protrusion on the syringe plunger.
    Patent expiration dates:
    • April 9, 2022
      ✓ 
      Drug product
  • Automatically operable safety shield system for syringes
    Patent 7,500,964
    Issued: March 10, 2009
    Inventor(s): Shaw; Derek J. & Law; Brian R.
    Assignee(s): AstraZeneca AB
    An automatically operable safety shield system for use with a syringe that comprises an inner holder in which said syringe may be inserted and an outer shield mounted outwards from the inner holder axially movable between retracted and extended positions in which a spring positioned between said inner holder and said outer shield urging the outer shield to its extended position and the inner holder having at least one first opening, distally thereto, at least one first indentation, and the outer shield having at least one first stop member engageable with the opening when the outer shield is in the retracted position engageable with the first indentation when the outer shield is in the extended position and the outer shield may be released from its retracted position by action of a trigger positioned within the inner holder or by protrusion on the syringe plunger.
    Patent expiration dates:
    • February 26, 2021
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide